ATE324435T1 - Virale zubereitungen, vektoren, immunogene und impfstoffe - Google Patents

Virale zubereitungen, vektoren, immunogene und impfstoffe

Info

Publication number
ATE324435T1
ATE324435T1 AT96903115T AT96903115T ATE324435T1 AT E324435 T1 ATE324435 T1 AT E324435T1 AT 96903115 T AT96903115 T AT 96903115T AT 96903115 T AT96903115 T AT 96903115T AT E324435 T1 ATE324435 T1 AT E324435T1
Authority
AT
Austria
Prior art keywords
virus
gene
immunomodulatory protein
site
genetic material
Prior art date
Application number
AT96903115T
Other languages
English (en)
Inventor
Stephen Charles Inglis
Michael Edward Griff Boursnell
Original Assignee
Cantab Pharmaceuticals Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9503395.7A external-priority patent/GB9503395D0/en
Priority claimed from GBGB9515557.8A external-priority patent/GB9515557D0/en
Priority claimed from GBGB9603322.0A external-priority patent/GB9603322D0/en
Application filed by Cantab Pharmaceuticals Res Ltd filed Critical Cantab Pharmaceuticals Res Ltd
Application granted granted Critical
Publication of ATE324435T1 publication Critical patent/ATE324435T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C12N2710/16662—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96903115T 1995-02-21 1996-02-21 Virale zubereitungen, vektoren, immunogene und impfstoffe ATE324435T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9503395.7A GB9503395D0 (en) 1995-02-21 1995-02-21 Viral,preparations,immunogens,and vaccines
GBGB9515557.8A GB9515557D0 (en) 1995-07-28 1995-07-28 Viral preparation,immunogens and vacciness
GBGB9603322.0A GB9603322D0 (en) 1996-02-16 1996-02-16 Viral preparations,immunogens and vaccines

Publications (1)

Publication Number Publication Date
ATE324435T1 true ATE324435T1 (de) 2006-05-15

Family

ID=27267593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96903115T ATE324435T1 (de) 1995-02-21 1996-02-21 Virale zubereitungen, vektoren, immunogene und impfstoffe

Country Status (9)

Country Link
US (4) US6287557B1 (de)
EP (2) EP1683858A3 (de)
JP (2) JPH11500014A (de)
AT (1) ATE324435T1 (de)
AU (1) AU711121B2 (de)
CA (1) CA2211743A1 (de)
DE (1) DE69636068T2 (de)
ES (1) ES2264136T3 (de)
WO (1) WO1996026267A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE324435T1 (de) * 1995-02-21 2006-05-15 Cantab Pharmaceuticals Res Ltd Virale zubereitungen, vektoren, immunogene und impfstoffe
US5851826A (en) * 1995-07-26 1998-12-22 Children's Medical Center Corporation Helper virus-free herpesvirus vector packaging system
US6344445B1 (en) 1995-10-19 2002-02-05 Cantab Pharmaceutical Research Limited Herpes virus vectors and their uses
WO1998029138A2 (en) 1996-12-27 1998-07-09 Instituto De Investigaciones Bioquimicas Fundacion Campomar Compositions and methods for tumour therapy
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US6277621B1 (en) 1998-02-26 2001-08-21 Medigene, Inc. Artificial chromosome constructs containing foreign nucleic acid sequences
GB9816775D0 (en) * 1998-07-31 1998-09-30 Efstathiou Stacey Herpesviral vectors for gene delivery
GB9816761D0 (en) 1998-07-31 1998-09-30 Phogen Limited Herpesvirus preparations and their uses
US6375952B1 (en) * 1998-08-07 2002-04-23 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
EP1038952A3 (de) * 1998-12-09 2001-06-27 Pfizer Products Inc. Verfahren zur Herstellung von Mareks Disease Virus (MDV) unter Verwendung von kontinuierlichen Vogelzellinien
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
AU6120600A (en) * 1999-06-08 2000-12-28 Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
US6764675B1 (en) * 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
ES2170622B1 (es) 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
DE60107203T3 (de) * 2000-01-21 2009-07-23 Biovex Ltd. Herpes-virusstämme für die gentherapie
GB0013817D0 (en) * 2000-06-06 2000-07-26 Univ Nottingham Trent Method for treating cells
US20030093819A1 (en) 2000-11-03 2003-05-15 D'andrea Alan D. Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
US20030188326A1 (en) * 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
DK1578771T3 (da) 2001-10-10 2013-06-10 Novo Nordisk As Remodellering og glycokonjugering af peptider
SE0201701D0 (sv) * 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
KR101114784B1 (ko) 2002-11-12 2012-02-27 예일 유니버시티 아데노바이러스 벡터 백신
CA2544946A1 (en) 2003-11-24 2005-03-06 Sidney Kimmel Cancer Center Mucin antigen vaccine
US8828957B2 (en) * 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
CN101583381B (zh) * 2006-09-08 2014-05-07 宾夕法尼亚大学董事会 Hsv-1和hsv-2疫苗和其使用方法
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
JP6144448B2 (ja) * 2006-12-28 2017-06-07 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 単純ヘルペスウイルス複合サブユニットワクチンおよびその使用方法
EP2529227B1 (de) * 2010-01-27 2015-10-07 Oregon Health & Science University Auf zytomegalovirus basierende immunogene zubereitungen
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
ES2788198T3 (es) 2010-05-14 2020-10-20 Univ Oregon Health & Science Vectores de CMVH y CMVRh recombinantes que codifican un antígeno heterólogo aislado del virus de la hepatitis B y usos de los mismos
LT2691530T (lt) 2011-06-10 2018-08-10 Oregon Health & Science University Cmv glikoproteinai ir rekombinantiniai vektoriai
WO2014138209A1 (en) 2013-03-05 2014-09-12 Oregon Health & Science University Cytomegalovirus vectors enabling control of t cell targeting
AU2015289560B2 (en) 2014-07-16 2018-09-27 Oregon Health & Science University Human cytomegalovirus comprising exogenous antigens
EP3256595A4 (de) 2015-02-10 2018-09-26 Oregon Health & Science University Verfahren und zusammensetzungen zur erzeugung nicht kanonischer cd8+t-zellantworten
CN116926128A (zh) 2015-11-20 2023-10-24 俄勒冈健康与科学大学 包含微小rna识别元件的cmv载体
BR112019007982A2 (pt) 2016-10-18 2019-07-02 Univ Oregon Health & Science vetores de citomegalovírus elicitando células t restringidas por moléculas do complexo de histocompatibilidade e principal
EP3624845A1 (de) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stabile virushaltige zusammensetzung
AU2018269319A1 (en) 2017-05-15 2019-11-07 Janssen Vaccines & Prevention B.V. Stable virus-containing composition

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
NL9020389A (nl) 1989-03-08 1991-12-02 Health Research Inc Systeem voor het in de gastheer selecteren van recombinant-pokkenvirussen.
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
WO1992005363A1 (en) * 1990-09-18 1992-04-02 Lucas Industries Public Limited Company Fuel injection nozzles
US5837261A (en) * 1990-09-25 1998-11-17 Cantab Pharmaceuticals Research Limited Viral vaccines
KR100372934B1 (ko) * 1990-09-25 2003-12-24 캔탑 파마슈티칼스 리서취 리미티드 형질 상보성 세포주에 의해 생성된 바이러스 결손 백신
US5665362A (en) * 1990-09-25 1997-09-09 Cantab Pharmaceuticals Research Limited Viral vaccines
US5849571A (en) * 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
HU218849B (hu) 1992-06-01 2000-12-28 American Cyanamid Co. Gazdaszervezetről gazdaszervezetre a környezetben csökkent terjedési képességgel rendelkező rekombináns bakulovirus és eljárás előállítására
DE69333751T2 (de) 1992-07-30 2005-12-29 Akzo Nobel N.V. Nicht-verbreitendes lebendes herpesvirusvakzin
US20020009462A1 (en) * 1992-07-31 2002-01-24 David M. Knipe Herpesvirus replication defective mutants
US5658724A (en) * 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
CA2141574C (en) * 1992-07-31 2009-11-24 David Knipe Herpesvirus vaccines
US5661033A (en) * 1992-11-25 1997-08-26 The Board Of Trustees Of The Leland Stanford Junior University Gene transfer using herpes virus vectors as a tool for neuroprotection
AU696336B2 (en) * 1993-03-19 1998-09-10 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. HSV) as vaccine
WO1994024296A2 (en) * 1993-04-19 1994-10-27 University Of Saskatchewan Recombinant bovine herpesvirus type 1 vaccines
ATE301201T1 (de) * 1993-06-07 2005-08-15 Vical Inc Für die gentherapie verwendbare plasmide
WO1995003399A2 (en) 1993-07-19 1995-02-02 Cantab Pharmaceuticals Research Limited Production method for preparation of disabled viruses
US5763217A (en) * 1993-11-10 1998-06-09 University Of British Columbia Method of using, process of preparing and composition comprising recombinant herpesvirus vectors
CA2158936C (en) * 1993-11-18 2012-02-21 Jack R. Barber Compositions and methods for utilizing conditionally lethal genes
US5693531A (en) * 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
US5763416A (en) * 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
ATE324435T1 (de) * 1995-02-21 2006-05-15 Cantab Pharmaceuticals Res Ltd Virale zubereitungen, vektoren, immunogene und impfstoffe
WO1996029421A1 (en) * 1995-03-23 1996-09-26 Cantab Pharmaceuticals Research Limited Vectors for gene delivery
US5851826A (en) * 1995-07-26 1998-12-22 Children's Medical Center Corporation Helper virus-free herpesvirus vector packaging system

Also Published As

Publication number Publication date
EP0811057A1 (de) 1997-12-10
DE69636068T2 (de) 2006-11-30
EP1683858A3 (de) 2006-08-02
ES2264136T3 (es) 2006-12-16
US20020150562A1 (en) 2002-10-17
DE69636068D1 (de) 2006-06-01
US20030091535A1 (en) 2003-05-15
CA2211743A1 (en) 1996-08-29
JPH11500014A (ja) 1999-01-06
WO1996026267A1 (en) 1996-08-29
AU4726396A (en) 1996-09-11
US20050118192A1 (en) 2005-06-02
AU711121B2 (en) 1999-10-07
EP1683858A2 (de) 2006-07-26
JP2007130022A (ja) 2007-05-31
EP0811057B1 (de) 2006-04-26
US6287557B1 (en) 2001-09-11

Similar Documents

Publication Publication Date Title
ATE324435T1 (de) Virale zubereitungen, vektoren, immunogene und impfstoffe
JP3895366B2 (ja) ウィルス ワクチン
IL164318A0 (en) Recombinant mva virus and vaccine comprising said virus
EP0882134B1 (de) Verfahren und zusammensetzungen zur genetisch schützenden und therapeutischen immunisierung
DE3853139D1 (de) Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
DK312687A (da) Varicella-zoster virus (vzv), fremgangsmaade til fremstilling deraf og vaccine indeholdende vzv
MY157873A (en) Recombinant mva virus, and the use thereof
MY134484A (en) Recombinant mva virus, and the use thereof
MY119381A (en) Recombinant mva virus, and the use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties